Search Results - application+%3e+therapeutics

776 Results

Sort By:

Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells

Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable. Researchers at the National Institute of Allergy and Infectious...

Published: 6/3/2026 | Updated: 6/3/2026 | Inventor(s): Ethan Shevach, Angela DeVico, Patricia Korty

Keywords(s):

Category(s): ResearchProducts, Application, Application > Diagnostics, Application > Therapeutics

A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions

The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...

Published: 5/14/2026 | Updated: 5/14/2026 | Inventor(s): Patrick Duffy, Jonathan Renn

Keywords(s):

Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy

Summary: Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees...

Published: 5/14/2026 | Updated: 5/14/2026 | Inventor(s): Steven Rosenberg, Sanghyun (Peter) Kim

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma

This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...

Published: 4/30/2026 | Updated: 4/30/2026 | Inventor(s): Sadhana Jackson

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration

Description of Technology: Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders from acute neural injuries (motor vehicle crashes, combat related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS), microglia help respond to CNS...

Published: 4/16/2026 | Updated: 4/16/2026 | Inventor(s): Wei Li, Jingxing Ou, Tantai Zhao

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Neurology, Collaboration Sought > Licensing

Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia

Summary: The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia. Description of Technology: Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis...

Published: 4/10/2026 | Updated: 4/10/2026 | Inventor(s): Vid Leko, Aidan Pursley, Kenichi Hanada, Zhiya Yu, Catherine Ade, James Yang

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases. Description of Technology: Retinitis...

Published: 3/24/2026 | Updated: 3/13/2026 | Inventor(s): S. Patricia Becerra, Alexandra Bernardo-Colon, Valeria Marigo, Andrea Bighinati

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE

Summary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases. Description of Technology: Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases...

Published: 3/11/2026 | Updated: 3/11/2026 | Inventor(s): S. Patricia Becerra, Rolf Swenson, Natarajan Raju, Alexandra Bernardo-Colon, Carolyn Woodroofe, Burchelle Blackman

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Humanized 40H3 Antibody

Summary: The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR. Description of Technology: Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have...

Published: 2/5/2026 | Updated: 2/5/2026 | Inventor(s): David Fitzgerald, Antonella Antignani, Robert Sarnovsky

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions

Summary: Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used...

Published: 5/12/2026 | Updated: 9/29/2025 | Inventor(s): Zheng-gang Liu, Swati Choksi, PeiXing Wan, Yeon-Ji Park

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Diagnostics, Application > Therapeutics

1 2 3 4 5 6 7 8 9 10 ...